Oral Solid Dosage Contract Manufacturing Market: Key Trends in Pharmaceutical Manufacturing
The Oral Solid Dosage Contract Manufacturing Market continues to play a central role in the global pharmaceutical supply chain. Oral solid dosage (OSD) contract manufacturing involves the outsourced production of oral medicines by a third-party company. These medicines include tablets, capsules, powders, and granules. A contract manufacturer can fulfill manufacturing, packaging, testing, and other production requirements. Pharmaceutical companies increasingly rely on specialized partners to reduce costs, increase production capacity, and accelerate time to market.
Oral Solid Dosage Contract Manufacturing Market size was valued at USD 10.07 billion in 2025. The market is anticipated to grow from USD 10.99 billion in 2026 to USD 22.62 billion by 2034, exhibiting a CAGR of 9.4% during the forecast period.
What Oral Solid Dosage Contract Manufacturing Entails
A Contract Manufacturing Organization (CMO) primarily provides manufacturing services, while a Contract Development and Manufacturing Organization (CDMO) supports both development and manufacturing. Within this landscape, an oral solid dosage CDMO offers end-to-end capabilities that help pharmaceutical companies navigate complex formulation and scale-up challenges. The process typically begins with formulation development, where the active pharmaceutical ingredient (API) and other raw materials are selected and tested. Materials are then mixed, and granulation may be performed to improve mixture quality. The prepared material is used to manufacture tablets or fill capsules. Coating is often applied either to protect the tablet or to control drug release. Finished products undergo rigorous quality testing for strength, quality, and purity before packaging, labeling, and serialization for distribution.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
Product and Mechanism Insights
According to Polaris Market Research, the tablets segment represented 33.10% of the market revenue in 2025 and remained the leading product segment. Tablets are widely used across different types of medicines due to their established manufacturing process, large production volumes, low manufacturing cost, and ease of administration. Demand for tablet contract manufacturing remains strong because of these inherent advantages.
The capsules segment is expected to grow at a CAGR of 10.80% during 2026–2034. Capsules are easy to use and provide faster drug release, making them a preferred dosage form. Benefits such as ease of swallowing, rapid disintegration, and absorption continue to drive interest in capsule production services. Technological advancements that enhance capsule-filling capabilities further support this segment.
On the mechanism side, controlled release formulations captured 43.50% market revenue in 2025 and formed the leading mechanism segment. This drug delivery approach sustains a steady drug concentration in tissues and the bloodstream for an extended period. The need for consistent and long-lasting drug delivery underpins sustained demand. Advances in oral controlled-release systems, including intestinal patches, polymer nanosystems, dome tablets, dual drug tablets, and bioinspired methods such as exosomes, continue to expand possibilities for manufacturers.
Regional Dynamics and Growth Drivers
North America accounted for 41.20% of the global market revenue in 2025, supported by rising investment in drug development and clinical research as well as an established pharmaceutical industry. Asia-Pacific is expected to witness the fastest growth during the forecast period with 11.80%, driven by strong manufacturing capacity and increasing pharmaceutical outsourcing. Large enterprises are projected to grow at a CAGR of 8.70% during 2026–2034 as many pharmaceutical companies continue to outsource production to improve efficiency and quality.
Key market drivers include rising pharmaceutical outsourcing and growing demand for generic medicines linked to patent expirations. Companies turn to CDMOs to utilize existing facilities rather than invest in new production sites. For example, Recipharm opened a new pilot-scale development center in Germany in February 2025 capable of producing GMP pilot-scale blends, granules, tablets, and hard capsules. Such investments by pharmaceutical outsourcing partners strengthen the overall ecosystem.
Key Market Participants
The Oral Solid Dosage Contract Manufacturing Market is highly competitive. Major companies include AbbVie Contract Manufacturing, Aenova Group, Alkem Laboratories Limited, Catalent, Inc., Dr. Reddy's Laboratories, Evonik, Famar, Granules India Limited, Jubilant Pharmova Limited, Lonza, Patheon Pharma Services (Thermo Fisher Scientific), Pfizer CentreOne, Piramal Pharma Solutions, Recipharm AB, and Vetter Pharma. These organizations focus on partnerships, capability expansion, and collaboration to strengthen their positions. Aenova Group, for instance, operates multiple manufacturing and development sites across Europe and the U.S. and offers tablet and capsule development, manufacturing, packaging, and supply services with an annual capacity exceeding 22 billion tablets and capsules. Piramal Pharma Solutions expanded its oral solid dosage capabilities through a dedicated facility investment with NewAmsterdam Pharma in August 2025 and later introduced commercial tablet-in-capsule technology.
Overall, the market benefits from advancements in drug delivery technology, sustained demand for oral solid forms (which account for almost two-thirds of prescription medications worldwide), and the strategic value of specialized manufacturing partners. Companies seeking reliable oral solid dosage CDMO relationships, robust tablet contract manufacturing, or advanced capsule production services can leverage the capabilities of established players to navigate regulatory requirements and scale production efficiently.
More Trending Latest Reports By Polaris Market Research:
top-20-companies-driving-change-in-edible-oil-market-2025
create-engaging-marketing-videos-with-ai-video-generator-market
competitive-analysis-of-top-10-companies-in-the-bioinformatics-market-2025
advancing-immunotherapy-with-top-5-immunotherapy-drug-companies
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Spiele
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness